Cochrane · systematic review · CD007941
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
Skoetz, N, Will, A, Monsef, I, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 1 · 14.3%Low 3 · 42.9%Moderate 1 · 14.3%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyEscalated BEACOPP versus chemotherapy including ABVD
Population: Patients with early unfavourable or advanced stage HL
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Escalated BEACOPP vs chemotherapy including ABVD | HR 0.74 [0.57, 0.97] | 5 studies · 3142 participants | High |
Progression, relapse or death Escalated BEACOPP vs chemotherapy including ABVD | HR 0.54 [0.45, 0.64] | 5 studies · 3142 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Adverse event: treatment‐related mortality Escalated BEACOPP vs chemotherapy including ABVD | RR 2.15 [0.93, 4.95] | 4 studies · 2700 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse event: secondary malignancies Escalated BEACOPP vs chemotherapy including ABVD | RR 1 [0.68, 1.48] | 5 studies · 3332 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse event: secondary malignancies: AML or MDS Escalated BEACOPP vs chemotherapy including ABVD | RR 3.9 [1.36, 11.21] | 5 studies · 3332 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse event: infertility (secondary amenorrhoea) Escalated BEACOPP vs chemotherapy including ABVD | RR 1.37 [0.83, 2.26] | 1 study · 106 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Quality of life Escalated BEACOPP vs chemotherapy including ABVD | no estimate extracted | NR | No studies |
Comparison
Population: patients with early unfavourable or advanced stage Hodgkin lymphoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OS | HR 0.8 | 4 studies · 2586 participants | Moderate |
PFS | HR 0.53 | 4 studies · 2586 participants | Moderate |
CR rate | RR 1.11 | 3 studies · 1245 participants | High |
Adverse events WHO grade III or IV | no estimate extracted | 3 studies · 2547 participants | Moderate |
Incidence of secondary malignancies | RR 0.95 [0.61, 1.48] | 3 studies · 2547 participants | Low |
Incidence of infertility | RR 1.37 | 1 study · 106 participants | Very low |
Treatment related mortality | RR 5.05 [0.25, 103.87] | 1 study · 197 participants | Very low |